Crown Bioscience has released another collection of life science products to its e-commerce platform.
CrownBio will add a significant number of cell lines and reference standards related to EGFR, KRAS, and BRAF signaling cascades of the MAPK pathway, which plays a critical role in the development and progression of cancer. Further enhancements to the CrownBio catalog also include additional monoclonal antibodies to immune checkpoint and cancer-related targets, as well as compounds to activate or inhibit signaling pathways.
This product expansion further strengthens CrownBio’s current product offerings within preclinical drug discovery and cancer research which already includes antibodies for in vivo and in vitro studies, recombinant proteins, recombinant cell lines, tumor samples for oncology research and development, and tumor tissue microarrays.
“The expansion of products validates our commitment to offer a complementary set of reagents, while further broadening the breath of products available from CrownBio. Furthermore, we have extended our customer service hours for more immediate and convenient access to our product support,” said Debby Saunders, Executive Director of Life Science Development at CrownBio.